Share price · PALI
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PALI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 16 Sep 2026-16.1%
Nothing announced by PALI that day or the session before.
- 13 Aug 2026+9.7%
Nothing announced by PALI that day or the session before.
- 12 Aug 2026-8.4%
Nothing announced by PALI that day or the session before.
- 29 Jun 2026+18.0%
- 22 Apr 2026-16.4%
Nothing announced by PALI that day or the session before.
- 21 Apr 2026+12.0%
Nothing announced by PALI that day or the session before.
- 15 Apr 2026+13.6%
Nothing announced by PALI that day or the session before.
- 30 Mar 2026-11.0%
- 5 Jan 2026-16.0%
Nothing announced by PALI that day or the session before.
Share of unusual movement by asset
For each asset, the share of PALI's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | PDE4Small molecule | Inflammatory Bowel Disease Ulcerative Colitis, Crohn's Disease |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $11M | $114M | $15M-$12M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0.5M | $7.4M | $125M | $11M-$7.6M operating cash flow | report ↗ |
| 2026-Q1 | — | $6.4M | $133M | $3.9M | report ↗ |
| 2025-Q3 | — | $1.4M | $5.2M | $2.9M-$3.5M operating cash flow | report ↗ |
| 2025-Q2 | — | $1.7M | $5.4M | $2.8M-$1.8M operating cash flow | report ↗ |
| 2025-Q1 | — | $0.9M | $7.2M | $2.2M-$2.3M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $2.1M | $8.0M | $3.5M-$3.1M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $2.6M | $11M | $4.1M-$3.5M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $2.2M | $11M | $3.5M-$3.2M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $1.7M | $15M | $3.6M-$2.7M operating cash flow | report ↗ |
| 2023-Q2 | $0 | $2.2M | $16M | $3.4M-$2.2M operating cash flow | report ↗ |
| 2023-Q1 | $0.3M | $1.2M | $13M | $2.3M-$3.5M operating cash flow | report ↗ |
| 2022-Q3 | $0 | $1.9M | $14M | $4.0M-$3.0M operating cash flow | report ↗ |
| 2022-Q2 | $0 | $1.3M | $5.0M | $2.3M-$3.3M operating cash flow | report ↗ |
| 2022-Q1 | $0 | $1.0M | $6.6M | $4.2M-$3.8M operating cash flow | report ↗ |
| 2021-Q3 | — | $0.6M | $14M | —-$2.8M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $10M | $133M | $4.2M-$11M operating cash flow | report ↗ |
For fiscal-year 2025, Palisade Bio did not disclose revenue (prior year $0M), reported R&D spend of $10.19M, up 12.5% YoY from $9.06M, cash and equivalents of $133.39M, and a net loss of $16.78M, with quarterly net burn of $16.78M.
Palisade Bio is advancing PALI-2108, a PDE4 inhibitor prodrug for inflammatory bowel disease. During the year, it completed dosing of 89 subjects in the Phase 1 study’s SAD, MAD, food-effect, and UC cohorts and reported positive safety, tolerability, and pharmacokinetic results. The company also dosed first patients in an exploratory Phase 1b fibrostenotic Crohn’s disease cohort in October 2025 and anticipates FDA IND submissions for a Phase 2 UC study in the second quarter of 2026 and a Phase 2 Crohn’s disease study in the second half of 2026.
Insider transactions
Open-market activity, trailing 12 months: 11 purchases ($347K), 4 sales ($420K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-17 | Baltera Robert Jr. · director | Open-market purchase | 50,000 | $1.01 | $50K | Form 4 |
| 2026-10-19 | Capers Julien E. · See Remarks | Award / grant | 787,300 | — | — | Form 4 |
| 2026-10-06 | Finley John David · director, CEO CFO | Option exercise | 3,227,384 | — | — | Form 4 |
| 2026-10-06 | Jones Mitchell Lawrence · See Remarks | Option exercise | 2,620,850 | — | — | Form 4 |
| 2026-10-06 | Finley John David · director, CEO CFO | Tax withholding | 1,411,982 | $1.49 | $2.1M | Form 4 |
| 2026-10-06 | Jones Mitchell Lawrence · See Remarks | Tax withholding | 1,031,102 | $1.49 | $1.5M | Form 4 |
| 2026-10-06 | Finley John David · director, CEO CFO | Option exercise (derivative) | 3,059,800 | — | — | Form 4 |
| 2026-10-06 | Jones Mitchell Lawrence · See Remarks | Option exercise (derivative) | 2,555,266 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 96 reporting institutions held 146.7M shares ($256.4M, 81.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | B Group, Inc. | 11,414,285 | $20.0M |
| 2 | JANUS HENDERSON GROUP PLC | 10,689,452 | $18.8M |
| 3 | Octagon Capital Advisors LP | 10,276,317 | $18.0M |
| 4 | PERCEPTIVE ADVISORS LLC | 8,928,149 | $15.6M |
| 5 | AMERIPRISE FINANCIAL INC | 8,711,385 | $15.2M |
| 6 | Commodore Capital LP | 7,181,062 | $12.6M |
| 7 | RA CAPITAL MANAGEMENT, L.P. | 7,124,116 | $12.5M |
| 8 | FRANKLIN RESOURCES INC | 5,785,189 | $10.1M |
| 9 | GOLDMAN SACHS GROUP INC | 5,373,951 | $9.4M |
| 10 | Eversept Partners, LP | 4,987,499 | $8.7M |
| 11 | Boxer Capital Management, LLC | 4,799,875 | $8.4M |
| 12 | MORGAN STANLEY | 4,551,533 | $8.0M |
| 13 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 4,500,000 | $7.9M |
| 14 | GREAT POINT PARTNERS LLC | 3,405,757 | $6.0M |
| 15 | Balyasny Asset Management L.P. | 3,270,845 | $5.7M |